Superluminal Medicines
Accelerating new possibilities in drug discovery and development
- Headquarters
- Boston, Massachusetts
- Business Model
- Other
- Website
- superluminalrx.com
- Last Round
- Seed
- Rounds
- 2
About
Superluminal Medicines is a Boston-based generative biology and chemistry company revolutionizing drug discovery with its Hyperloop™ Platform. This platform integrates cutting-edge structure-based drug discovery, AI-powered computational methods, and experimental validation to develop small molecule therapeutics targeting GPCRs for cardiometabolic diseases. Recently, they announced a collaboration with Eli Lilly potentially worth up to $1.3 billion.
Summary
Superluminal Medicines is a Life Sciences company based in Boston, United States. Investors include RA Capital Management, Insight Partners and Nvidia.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Unknown
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
PHC is a leading provider of diabetes monitoring systems, specialized laboratory equipment, and c...
BridgeBio makes targeted treatments for genetic diseases.